Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis

Tamoxifen (TMX) is used as adjuvant therapy for estrogen receptor-positive (ER+) breast cancer cases due to its affinity and inhibitory effects. However, about 30% of cases show drug resistance, resulting in recurrence and metastasis, the leading causes of death. A literature review can help to eluc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal Berto, Maiquidieli, dos Santos, Giovana Tavares, dos Santos, Aniúsca Vieira, Silva, Andrew Oliveira, Vargas, José Eduardo, Alves, Rafael José Vargas, Barbisan, Fernanda, da Cruz, Ivana Beatrice Mânica, Bica, Claudia Giuliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777552/
https://www.ncbi.nlm.nih.gov/pubmed/35201456
http://dx.doi.org/10.1007/s12672-021-00432-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777552/
https://www.ncbi.nlm.nih.gov/pubmed/35201456
http://dx.doi.org/10.1007/s12672-021-00432-7

Ejemplares similares